Modern Rheumatology

, 18:306 | Cite as

Treatment of retinal vasculitis in Behçet's disease with rituximab

  • Shahram Sadreddini
  • Hamid Noshad
  • Mahshid Molaeefard
  • Rahim Noshad
Case Report


Behçet's disease (BD) is more common in eastern than western countries. Physicians have frequently encountered problems in its treatment, especially eye involvement. Recurrent oral and genital aphthous ulcerations are the hallmarks of Behçet’s disease but other organs can be involved and ocular disease is one of the most disabling manifestations. Up to now, there are some problems in treatment of the retinal vasculitis due to Behçet’s disease. We reported one patient, with visual loss due to retinal vasculitis that was resistant to prednisolone and azathioprine. Our patient was treated successfully with rituximab and his remission was sustained for 24 months of follow-up. Rituximab is a chimeric monoclonal antibody that acts against the specific B cell antigen, CD20. The recent success of rituximab in autoimmune diseases, which is considered to be T cell-mediated, indicates that B cells must have a much broader role in the pathogenesis of autoimmune diseases than generally appreciated.


Rituximab Behçet's disease Retinal vasculitis 


  1. 1.
    Porter SR, Al-Otaibi LM, Poate TWJ. Behçet’s disease: a review. J Dent Res. 2005;84:209–22.PubMedCrossRefGoogle Scholar
  2. 2.
    Kansu T, Kadayifcilar S. Visual aspects of Behçet’s disease. Curr Treat Options Neurol. 2007;8:81–8.CrossRefGoogle Scholar
  3. 3.
    Stashenko P, Nadler LM, Hardy R, Schlossman SF. Characterization of a human B lymphocyte-specific antigen. J Immunol. 1980;125:1678–85.PubMedGoogle Scholar
  4. 4.
    Davachi F. New and innovative therapies for Behçet’s disease. APLAR J Rheum. 2004;7:141–5.CrossRefGoogle Scholar
  5. 5.
    Kneitz C, Wilhelm M, Tony H. Effective B cell depletion with rituximab in treatment of autoimmune diseases. J Immunobiol. 2002;206:519–27.CrossRefGoogle Scholar
  6. 6.
    Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003;22:7359–68.PubMedCrossRefGoogle Scholar
  7. 7.
    Edwards JCW, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, et al. Efficacy of B-cell–targeted therapy with rituximab in patients with rheumatoid arthritis. New Engl J Med. 2004; 350:2572–81.PubMedCrossRefGoogle Scholar
  8. 8.
    Cheung CM, Murray PI, Savage CO. Successful treatment of Wegener’s granulomatosis associated scleritis with rituximab. Br J Ophthalmol. 2005;89:1542.PubMedCrossRefGoogle Scholar
  9. 9.
    Ahmadi-Simab K, Lamprecht P, Nolle B, Ai M. Successful treatment of refractory anterior scleritis in primary Sjogren's syndrome with rituximab. Ann Rheum Dis. 2005;64:1087–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Kaushik VV, Reddy HV, BucknalR C. Successful use of rituximab in a patient with recalcitrant Churg-Strauss syndrome. Ann Rheum Dis. 2006;65:1116–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Eksioglu-Demiralp E, Kibaroglu A, Direskeneli H, et al. Phenotypic characteristics of B cells in Behçet's disease: increased activity in B cell subsets. J Rheumatol. 1999;26:826–32.PubMedGoogle Scholar
  12. 12.
    Looney RJ, Anolik JH, Campbell D, Felgar RE, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 2004;50:2580–9.PubMedCrossRefGoogle Scholar

Copyright information

© Japan College of Rheumatology 2008

Authors and Affiliations

  • Shahram Sadreddini
    • 1
  • Hamid Noshad
    • 1
  • Mahshid Molaeefard
    • 2
  • Rahim Noshad
    • 3
  1. 1.Tabriz University of Medical SciencesTabrizIran
  2. 2.Tehran University of Medical SciencesTehranIran
  3. 3.Alavi HospitalTabriz University of Medical Sciences, 522 Military HospitalTabrizIran

Personalised recommendations